173 related articles for article (PubMed ID: 35166240)
1. Epigenomic reprogramming via HRP2-MINA dictates response to proteasome inhibitors in multiple myeloma with t(4;14) translocation.
Wang J; Zhu X; Dang L; Jiang H; Xie Y; Li X; Guo J; Wang Y; Peng Z; Wang M; Wang J; Wang S; Li Q; Wang Y; Wang Q; Ye L; Zhang L; Liu Z
J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166240
[TBL] [Abstract][Full Text] [Related]
2. Targeting NSD2-mediated SRC-3 liquid-liquid phase separation sensitizes bortezomib treatment in multiple myeloma.
Liu J; Xie Y; Guo J; Li X; Wang J; Jiang H; Peng Z; Wang J; Wang S; Li Q; Ye L; Zhong Y; Zhang Q; Liu X; Lonard DM; Wang J; O'Malley BW; Liu Z
Nat Commun; 2021 Feb; 12(1):1022. PubMed ID: 33589584
[TBL] [Abstract][Full Text] [Related]
3. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma.
Cheong CM; Mrozik KM; Hewett DR; Bell E; Panagopoulos V; Noll JE; Licht JD; Gronthos S; Zannettino ACW; Vandyke K
Cancer Lett; 2020 Apr; 475():99-108. PubMed ID: 32014459
[TBL] [Abstract][Full Text] [Related]
4. Posttranslational modification of Aurora A-NSD2 loop contributes to drug resistance in t(4;14) multiple myeloma.
Jiang H; Wang Y; Wang J; Wang Y; Wang S; He E; Guo J; Xie Y; Wang J; Li X; Peng Z; Wang M; Hou J; Liu Z
Clin Transl Med; 2022 Apr; 12(4):e744. PubMed ID: 35389552
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
Keats JJ; Maxwell CA; Taylor BJ; Hendzel MJ; Chesi M; Bergsagel PL; Larratt LM; Mant MJ; Reiman T; Belch AR; Pilarski LM
Blood; 2005 May; 105(10):4060-9. PubMed ID: 15677557
[TBL] [Abstract][Full Text] [Related]
6. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma.
Qiang YW; Ye S; Chen Y; Buros AF; Edmonson R; van Rhee F; Barlogie B; Epstein J; Morgan GJ; Davies FE
Blood; 2016 Dec; 128(25):2919-2930. PubMed ID: 27793878
[TBL] [Abstract][Full Text] [Related]
7. The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity.
He L; Yu C; Qin S; Zheng E; Liu X; Liu Y; Yu S; Liu Y; Dou X; Shang Z; Wang Y; Wang Y; Zhou X; Liu B; Zhong Y; Liu Z; Lu J; Sun L
Mol Cell; 2023 Nov; 83(22):4000-4016.e6. PubMed ID: 37935198
[TBL] [Abstract][Full Text] [Related]
8. Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.
Otsuki T; Yamada O; Yata K; Sakaguchi H; Kurebayashi J; Nakazawa N; Taniwaki M; Yawata Y; Ueki A
Int J Oncol; 1999 Dec; 15(6):1205-12. PubMed ID: 10568829
[TBL] [Abstract][Full Text] [Related]
9. SMARCA2 Is a Novel Interactor of NSD2 and Regulates Prometastatic
Chong PSY; Chooi JY; Lim JSL; Toh SHM; Tan TZ; Chng WJ
Cancer Res; 2021 May; 81(9):2332-2344. PubMed ID: 33602783
[TBL] [Abstract][Full Text] [Related]
10. Proteasome inhibitor induced SIRT1 deacetylates GLI2 to enhance hedgehog signaling activity and drug resistance in multiple myeloma.
Xie Y; Liu J; Jiang H; Wang J; Li X; Wang J; Zhu S; Guo J; Li T; Zhong Y; Zhang Q; Liu Z
Oncogene; 2020 Jan; 39(4):922-934. PubMed ID: 31576013
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia induces chemoresistance to proteasome inhibitors through orchestrating deSUMOylation and ubiquitination of SRC-3 in multiple myeloma.
Guo J; Lv Y; Wang S; Peng Z; Xie Y; Wang Y; Jiang H; Li X; Wang M; Hu M; Mu J; Wang J; Xie Y; Cheng X; Zhao Z; Liu Z
Oncogene; 2022 Nov; 41(45):4971-4979. PubMed ID: 36209257
[TBL] [Abstract][Full Text] [Related]
12. CD221 (IGF-1R) is aberrantly expressed in multiple myeloma, in relation to disease severity.
Bataille R; Robillard N; Avet-Loiseau H; Harousseau JL; Moreau P
Haematologica; 2005 May; 90(5):706-7. PubMed ID: 15921396
[TBL] [Abstract][Full Text] [Related]
13. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity.
Lauring J; Abukhdeir AM; Konishi H; Garay JP; Gustin JP; Wang Q; Arceci RJ; Matsui W; Park BH
Blood; 2008 Jan; 111(2):856-64. PubMed ID: 17942756
[TBL] [Abstract][Full Text] [Related]
14. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
15. The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells.
Martinez-Garcia E; Popovic R; Min DJ; Sweet SM; Thomas PM; Zamdborg L; Heffner A; Will C; Lamy L; Staudt LM; Levens DL; Kelleher NL; Licht JD
Blood; 2011 Jan; 117(1):211-20. PubMed ID: 20974671
[TBL] [Abstract][Full Text] [Related]
16. The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.
Longo J; Smirnov P; Li Z; Branchard E; van Leeuwen JE; Licht JD; Haibe-Kains B; Andrews DW; Keats JJ; Pugh TJ; Trudel S; Penn LZ
Leukemia; 2021 Mar; 35(3):796-808. PubMed ID: 32665698
[TBL] [Abstract][Full Text] [Related]
17. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
18. Timing of acquisition of deletion 13 in plasma cell dyscrasias is dependent on genetic context.
Chiecchio L; Dagrada GP; Ibrahim AH; Dachs Cabanas E; Protheroe RK; Stockley DM; Orchard KH; Cross NC; Harrison CJ; Ross FM;
Haematologica; 2009 Dec; 94(12):1708-13. PubMed ID: 19996118
[TBL] [Abstract][Full Text] [Related]
19. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma.
Choudhury SR; Ashby C; Tytarenko R; Bauer M; Wang Y; Deshpande S; Den J; Schinke C; Zangari M; Thanendrarajan S; Davies FE; van Rhee F; Morgan GJ; Walker BA
J Hematol Oncol; 2020 Aug; 13(1):108. PubMed ID: 32762714
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
